other material
confidence high
sentiment neutral
materiality 0.50
PAVmed subsidiary Lucid Diagnostics closes ~$15.3M equity offering at $1.10/share
PAVmed Inc.
- Lucid Diagnostics sold 13.9M shares at $1.10 each, gross proceeds ~$15.3M.
- Net proceeds estimated ~$14.5M after placement agent fees and expenses.
- Proceeds expected to be used for working capital and general corporate purposes.
- Offering closed on March 5, 2025, pursuant to an existing shelf registration statement.